Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Maintenance of autoantibody production in pristane-induced murine lupus

Fig. 1

Splenic CD19+ B cells from pristane-treated mice are hyper-responsive to synthetic toll-like receptor (TLR)7 ligand and apoptotic cells. a Purified (magnetic beads) splenic CD19+ B cells from pristane-treated (one year) or PBS treated mice were stimulated by PBS or TLR ligands R848 (TLR7), lipopolysaccharide (LPS) (TLR4) and CpG1826 (TLR9) for 10 days. IgG was measured in culture supernatants (ELISA). b Splenic CD19+ B cells were stimulated by PBS or apoptotic BW5147 cells (Apo cells) (Apo cells: B cells = 1:1) and IgG was measured 10 days later by ELISA. c CD19+ B cells were stimulated by R848 or apoptotic cells with addition of ODN 2088 (0.1 μM) or ODN 20958 (0.1 μM), and IgG was measured 10 days later by ELISA. d TLR7−/− and wild type mice were treated with pristane for 3 months. Purified splenic CD19+ B cells were stimulated with PBS, R848 (1 μg/ml), or apoptotic BW5147 (Apo cells: B cells = 1:1). IgG in culture supernatants was measured 10 days later by ELISA. e R848 dose–response curves for CD19+ B cells from pristane-treated vs. PBS treated mice. IgG levels were measured by ELISA. f CD19+ B cells were cultured with R848 with/without the addition of recombinant murine BAFF (5 ng/ml, Biolegend) followed by measurement of IgG in culture supernatants (ELISA). g Tlr7 and Unc93b1 mRNA expression level (compared to 18S rRNA) in pristane-treated vs. PBS treated splenic CD19+ B cells (Q-PCR): *p <0.05; **p <0.01, paired Student t test. BAFF B cell activating factor

Back to article page
\